Journal of Tuberculosis and Lung Disease ›› 2021, Vol. 2 ›› Issue (1): 78-82.doi: 10.3969/j.issn.2096-8493.2021.01.017
• Review Articles • Previous Articles Next Articles
GUI Min1, CHEN Jing-fang1,2(), DENG Guo-fang3, FU Liang3, ZENG Gu-qing1
Received:
2020-11-22
Online:
2021-03-30
Published:
2021-03-24
Contact:
CHEN Jing-fang
E-mail:13823139640@163.com
GUI Min, CHEN Jing-fang, DENG Guo-fang, FU Liang, ZENG Gu-qing. Research progress on the effectiveness and adverse reactions of clofazimine in the treatment of multidrug-resistant tuberculosis[J]. Journal of Tuberculosis and Lung Disease , 2021, 2(1): 78-82. doi: 10.3969/j.issn.2096-8493.2021.01.017
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.jtbld.cn/EN/10.3969/j.issn.2096-8493.2021.01.017
[1] | 马啸楠, 龚军侠, 石海萍. 氯法齐明联合二线药物治疗耐多药结核病18个月转阴率、临床疗效及不良反应观察. 中国煤炭工业医学杂志, 2019,22(4):371-374. doi: 10.11723/mtgyyx 1007-9564 201904008. |
[2] | 冯宇. 氯法齐明联合方案治疗耐多药结核病的疗效. 航空航天医学杂志, 2019,30(11):1378-1380. |
[3] | 李学玲, 陈晓红, 翁丽珍, 等. 含氯法齐明的联合化疗方案对耐多药肺结核的临床疗效观察. 中国临床医生杂志, 2019,47(1):46-48. doi: 10.3969/j.issn.2095-8552.2019.01.015. |
[4] |
Du Y, Qiu C, Chen X, et al. Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China. Clin Infect Dis, 2020,71(4):1047-1054. doi: 10.1093/cid/ciz915.
doi: 10.1093/cid/ciz915 URL pmid: 31549147 |
[5] | 李荣珍, 赵智慧, 李涛. 氯法齐明联合方案治疗多重耐药肺结核的疗效及安全性. 中国医院用药评价与分析, 2018,18(3):320-322. doi: 10.14009/j.issn.1672-2124.2018.03.009. |
[6] | 石海萍, 刘云. 氯法齐明联合方案治疗致耐多药结核病的疗效及安全性. 医学综述, 2017,23(2):394-397. doi: 10.3969/j.issn.1006-2084.2017.02.044. |
[7] |
Cholo MC, Steel HC, Fourie PB, et al. Clofazimine: current status and future prospects. J Antimicrob Chemother, 2012,67(2):290-298. doi: 10.1093/jac/dkr444.
doi: 10.1093/jac/dkr444 URL pmid: 22020137 |
[8] |
Rojo A, Ibáñez MA, Alonso CA, et al. Multidrug-resistant tuberculosis presenting as a solitary splenic mass in an immunocompetent patient. Diagn Microbiol Infect Dis, 2011,70(4):522-524. doi: 10.1016/j.diagmicrobio.2011.03.013.
doi: 10.1016/j.diagmicrobio.2011.03.013 URL pmid: 21767708 |
[9] | 中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019,42(10):733-749. doi: 10.3760/cma.j.issn.1001-0939.2019.10.006. |
[10] |
Oliva B, O’Neill AJ, Miller K, et al. Anti-staphylococcal activity and mode of action of clofazimine. J Antimicrob Chemother, 2004,53(3):435-440. doi: 10.1093/jac/dkh114.
doi: 10.1093/jac/dkh114 URL pmid: 14762055 |
[11] |
Yano T, Kassovska-Bratinova S, Teh JS, et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem, 2011,286(12):10276-10287. doi: 10.1074/jbc.M110.200501.
doi: 10.1074/jbc.M110.200501 URL pmid: 21193400 |
[12] |
Parak RB, Wadee AA. The synergistic effects of gamma interferon and clofazimine on phagocyte function: restoration of inhibition due to a 25 kilodalton fraction from Mycobacterium tuberculosis. Biotherapy, 1991,3(3):265-272. doi: 10.1007/BF02171691.
doi: 10.1007/BF02171691 URL pmid: 1906725 |
[13] |
Wadee AA, Anderson R, Rabson AR. Clofazimine reverses the inhibitory effect of Mycobacterium tuberculosis derived factors on phagocyte intracellular killing mechanisms. J Antimicrob Chemother, 1988,21(1):65-74. doi: 10.1093/jac/21.1.65.
doi: 10.1093/jac/21.1.65 URL pmid: 3128522 |
[14] |
Shen GH, Wu BD, Hu ST, et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents, 2010,35(4):400-404. doi: 10.1016/j.ijantimicag.2009.12.008.
doi: 10.1016/j.ijantimicag.2009.12.008 URL pmid: 20138481 |
[15] |
Mothiba MT, Anderson R, Fourie B, et al. Effects of clofazimine on planktonic and biofilm growth of Mycobacterium tuberculosis and Mycobacterium smegmatis. J Glob Antimicrob Resist, 2015,3(1):13-18. doi: 10.1016/j.jgar.2014.12.001.
doi: 10.1016/j.jgar.2014.12.001 URL pmid: 27873644 |
[16] | World Health Organization. World Health Organization treatment guidelines for drug-resistant tuberculosis,2016. Geneva:World Health Organization, 2016. |
[17] | World Health Organization. Position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage 1 preliminary results. Geneva:World Health Organization, 2018. |
[18] |
Javaid A, Ahmad N, Khan AH, et al. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Eur Respir J, 2017,49(1):1601967. doi: 10.1183/13993003.01967-2016.
doi: 10.1183/13993003.01967-2016 URL pmid: 28049176 |
[19] |
van der Werf MJ, Hollo V, Ködmön C, et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J, 2017,49(3):1601992. doi: 10.1183/13993003.01992-2016.
doi: 10.1183/13993003.01992-2016 URL pmid: 28331041 |
[20] |
Dalcolmo M, Gayoso R, Sotgiu G, et al. Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000—2015. Eur Respir J, 2017,49(4):1602309. doi: 10.1183/13993003.02309-2016.
doi: 10.1183/13993003.02309-2016 URL pmid: 28404651 |
[21] |
Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis, 2014,18(10):1188-1194. doi: 10.5588/ijtld.13.0075.
doi: 10.5588/ijtld.13.0075 URL pmid: 25216832 |
[22] |
Aung KJ, Van Deun A, Declercq E, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis, 2014,18(10):1180-1187. doi: 10.5588/ijtld.14.0100.
doi: 10.5588/ijtld.14.0100 URL pmid: 25216831 |
[23] |
Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2019,200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.
doi: 10.1164/rccm.201909-1874ST URL pmid: 31729908 |
[24] |
Padayatchi N, Gopal M, Naidoo R, et al. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. J Antimicrob Chemother, 2014,69(11):3103-3107. doi: 10.1093/jac/dku235.
doi: 10.1093/jac/dku235 URL pmid: 24986495 |
[25] |
Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med, 2015,191(8):943-953. doi: 10.1164/rccm.201410-1801OC.
doi: 10.1164/rccm.201410-1801OC URL pmid: 25622149 |
[26] |
Dalcolmo M, Gayoso R, Sotgiu G, et al. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J, 2017,49(3):1602445. doi: 10.1183/13993003.02445-2016.
doi: 10.1183/13993003.02445-2016 URL pmid: 28331044 |
[27] |
Gopal M, Padayatchi N, Metcalfe JZ, et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis, 2013,17(8):1001-1007. doi: 10.5588/ijtld.12.0144.
doi: 10.5588/ijtld.12.0144 URL pmid: 23541151 |
[28] |
Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis, 2015,60(9):1361-1367. doi: 10.1093/cid/civ027.
doi: 10.1093/cid/civ027 URL pmid: 25605283 |
[29] |
Duan H, Chen X, Li Z, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect, 2019,25(2):190-195. doi: 10.1016/j.cmi.2018.07.012.
doi: 10.1016/j.cmi.2018.07.012 URL pmid: 30036672 |
[30] |
Pang Y, Lu J, Huo F, et al. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review. J Infect, 2017,75(5):433-440. doi: 10.1016/j.jinf.2017.08.005.
doi: 10.1016/j.jinf.2017.08.005 URL pmid: 28804028 |
[31] |
Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J, 2014,45(1):161-170. doi: 10.1183/09031936.00035114.
doi: 10.1183/09031936.00035114 URL pmid: 25234807 |
[32] | 张建武, 王芳, 王燕波, 等. 含氯法齐明联合方案治疗耐多药肺结核患者的临床疗效和安全性. 中国生化药物杂志, 2016,36(12):103-106,110. doi: 10.3969/j.issn.1005-1678.2016.12.029. |
[33] | 许桂桃, 赵利军. 含氯法齐明联合方案运用于耐多药结核治疗中的效果观察. 世界最新医学信息文摘, 2016,16(89):116. doi: 10.3969/j.issn.1671-3141.2016.89.105. |
[34] | 石海萍, 韩莉. 含氯法齐明方案治疗耐多药肺结核近期疗效观察. 陕西医学杂志, 2015,44(5):605-607. doi: 10.3969/j.issn.1000-7377.2015.05.038. |
[35] | 首都医科大学附属北京胸科医院, 中国防痨协会临床试验专业分会, 《中国防痨杂志》编辑委员会. 氯法齐明治疗结核病的临床应用指南. 中国防痨杂志, 2020,42(5):409-417. doi: 10.3969/j.issn.1000-6621.2020.05.001. |
[36] |
Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010,182(5):684-692. doi: 10.1164/rccm.201001-0077OC.
doi: 10.1164/rccm.201001-0077OC URL pmid: 20442432 |
[37] |
Trébucq A, Schwoebel V, Kashongwe Z, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis, 2018,22(1):17-25. doi: 10.5588/ijtld.17.0498.
doi: 10.5588/ijtld.17.0498 URL pmid: 29149917 |
[38] |
Kuaban C, Noeske J, Rieder HL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis, 2015,19(5):517-524. doi: 10.5588/ijtld.14.0535.
doi: 10.5588/ijtld.14.0535 URL pmid: 25868018 |
[39] |
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018,392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
doi: 10.1016/S0140-6736(18)31644-1 URL pmid: 30215381 |
[40] |
Sun F, Li Y, Chen Y, et al. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study. Eur Respir J, 2019,53(3):1801770. doi: 10.1183/13993003.01770-2018.
doi: 10.1183/13993003.01770-2018 URL pmid: 30578402 |
[41] | 中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019,41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001. |
[42] | 周明广, 李艳杰, 徐建国. 氯法齐明治疗耐多药结核病临床观察. 吉林医学, 2012,33(4):779. doi: 10.3969/j.issn.1004-0412.2012.04.065. |
[43] |
Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf, 2015,38(3):253-269. doi: 10.1007/s40264-015-0267-y.
doi: 10.1007/s40264-015-0267-y URL pmid: 25676682 |
[44] |
O’Donnell MR, Padayatchi N, Metcalfe JZ. Elucidating the role of clofazimine for the treatment of tuberculosis. Int J Tuberc Lung Dis, 2016,20(12):52-57. doi: 10.5588/ijtld.16.0073.
doi: 10.5588/ijtld.16.0073 URL pmid: 28240574 |
[45] |
Xu HB, Jiang RH, Tang SJ, et al. Notice of retraction. Role of clofazimine in the treatment of multidrug-resistant tuberculosis: a retrospective observational cohort assessment. J Antimicrob Chemother, 2014,69(3):e1. doi: 10.1093/jac/dks077.
doi: 10.1093/jac/dks077 URL pmid: 22396431 |
[46] |
Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother, 2013,68(2):284-293. doi: 10.1093/jac/dks389.
doi: 10.1093/jac/dks389 URL pmid: 23054996 |
[47] | 程武, 谭守勇, 李艳. 16例耐多药肺结核患者服用氯法齐明后的不良反应分析. 结核病与肺部健康杂志, 2016,5(3):247-249. doi: 10.3969/j.issn.2095-3755.2016.03.020. |
[48] |
Tadolini M, Lingtsang RD, Tiberi S, et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J, 2016,48(5):1527-1529. doi: 10.1183/13993003.01552-2016.
doi: 10.1183/13993003.01552-2016 URL pmid: 27799401 |
[49] |
Wallis RS. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J, 2016,48(5):1526-1527. doi: 10.1183/13993003.01207-2016.
doi: 10.1183/13993003.01207-2016 URL pmid: 27799400 |
[50] |
Silva DR, Dalcolmo M, Tiberi S, et al. New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis. J Bras Pneumol, 2018,44(2):153-160. doi: 10.1590/s1806-37562017000000436.
doi: 10.1590/s1806-37562017000000436 URL pmid: 29791557 |
[51] |
Anderson R, Theron AJ, Nel JG, et al. Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro. Front Pharmacol, 2018,9:1335. doi: 10.3389/fphar.2018.01335.
doi: 10.3389/fphar.2018.01335 URL pmid: 30515097 |
[52] |
Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med, 2020,8(4):383-394. doi: 10.1016/S2213-2600(20)30047-3.
doi: 10.1016/S2213-2600(20)30047-3 URL pmid: 32192585 |
[53] | World Health Organization. WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis,2018 update. Geneva:World Health Organization, 2018. |
[54] |
Hwang TJ, Dotsenko S, Jafarov A, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open, 2014,4(1):e004143. doi: 10.1136/bmjopen-2013-004143.
doi: 10.1136/bmjopen-2013-004143 URL pmid: 24384902 |
[1] | ZHANG Zhi-guo, GUO Hai-ping, PANG Yu. Considerations for the application of laboratory diagnostics in detecting drug-resistant tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 13-17. |
[2] | WANG Zhi-hui, DONG Ya-kun, CHI Yue-peng, DI Hong-qin, LIANG Ya-chong, XIE Lan-pin. Evaluation of the application value of fluorescence PCR probe melting curve method in detecting drug resistance in elderly pulmonary tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 18-22. |
[3] | WANG Lian-bo, ZHANG Zhi-hua, LIU Feng-sheng, JIA Chen-guang, DONG Zhao-liang, YAO Xiao-wei, WU Shu-cai. Application value of GeneXpert MTB/RIF in diagnosis of joint tuberculosis and detection of rifampin resistance [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 23-25. |
[4] | ZHANG Zhe-nan, JIANG Nan-yang, WANG Wei, JIANG Lian-ju, LIU Yu-qin. Analysis of the effectiveness of two different surgical methods on treating cervical lymph node tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 26-30. |
[5] | XIAO Juan, PI Hong-lin, SUN Qing-peng. Analysis of clinical characteristics and therapeutic effect of 96 patients with spinal tuberculosis underwent surgical treatment [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 38-42. |
[6] | LI Yuan, GAO Feng-hua, JIN Feng. Evaluation of treatment and management effect of DOTS combined with WeChat on pulmonary tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 50-53. |
[7] | FANG Lan-jun, WU Hui-zhong, HUANG Shan-shan, WEN Wen-pei, ZHOU Lin, CHEN Liang. Evaluation of intervention effect of WeChat health education on the knowledge, belief, and behavior of tuberculosis prevention and treatment in college freshmen [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 54-57. |
[8] | SUN Ming-lei, GUAN Li, LIANG Li-bo, ZHAO Juan, WANG Chen, ZOU Dan-dan. Bibliometric analysis of tuberculosis patient and care system delay based on Web of Science core database [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 62-68. |
[9] | JIAO Wei-wei. Advances in molecular diagnostic techniques of tuberculosis in children [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 69-72. |
[10] | GUI Xu-wei, KE Hui, GU Jin. Progress of diagnostic research in biomarkers tuberculous pleurisy [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 73-77. |
[11] | HAN Li-jun, ZHAO Xue-yao. Molecular detection technologies for diagnosing tuberculous meningitis using cerebrospinal fluid [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 8-12. |
[12] | HAN Mei, HAN Pu, CHEN Ya-ting, YANG Song, YAN Xiao-feng. Study progress on the application of sputum induction in the etiological diagnosis of pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 83-87. |
[13] | ZHU Guo-feng, LIU Xiao-qing. The new era of systematic immunology of tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 195-212. |
[14] | YI Jun-li, YANG Xin-yu, ZHANG Jie, TIAN Li-li, DING Bei-chuan, WU Wen-qing. Application evaluation of three methods for identification between Mycobacterium tuberculosis complex and non-tuberculous mycobacteria [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 240-244. |
[15] | SU Bi-yi, ZHOU De-wang, MA Pin-yun, GUAN Ping, TAN Yao-ju. Diagnostic value of melting curve method in detecting resistance of Mycobacterium tuberculosis to rifampicin and isoniazid [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 245-248. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||